<code id='467446AF82'></code><style id='467446AF82'></style>
    • <acronym id='467446AF82'></acronym>
      <center id='467446AF82'><center id='467446AF82'><tfoot id='467446AF82'></tfoot></center><abbr id='467446AF82'><dir id='467446AF82'><tfoot id='467446AF82'></tfoot><noframes id='467446AF82'>

    • <optgroup id='467446AF82'><strike id='467446AF82'><sup id='467446AF82'></sup></strike><code id='467446AF82'></code></optgroup>
        1. <b id='467446AF82'><label id='467446AF82'><select id='467446AF82'><dt id='467446AF82'><span id='467446AF82'></span></dt></select></label></b><u id='467446AF82'></u>
          <i id='467446AF82'><strike id='467446AF82'><tt id='467446AF82'><pre id='467446AF82'></pre></tt></strike></i>

          Home / fashion / leisure time

          leisure time


          leisure time

          author:leisure time    Page View:57815
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In